Perspective Therapeutics (CATX) investor relations material

Executive summary

• Advanced three clinical-stage oncology programs (VMT-α-NET, VMT01, PSV359), with VMT-α-NET progressing toward a registration-enabling study and multiple clinical catalysts expected in 2026.

• Expanded manufacturing capabilities in the U.S., with Chicago site construction expected to complete in 2026 to support clinical and potential commercial supply.

• Presented updated clinical data for lead programs, ongoing regulatory engagement, and new intellectual property issued.

• Cash runway projected into late 2027, supported by $271M in cash, cash equivalents, and short-term investments as of March 31, 2026.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $271M as of March 31, 2026, up from $145M at year-end 2025, following a $164M–$175M equity offering in February 2026.

• Net loss for Q1 2026 was $26.2M ($0.25 per share), compared to $18.2M ($0.25 per share) in Q1 2025.

• Research and development expenses rose to $21.4M for Q1 2026, driven by higher personnel and clinical trial costs.

• General and administrative expenses decreased to $7.0M for Q1 2026, mainly due to lower professional and consulting fees.

• Operating cash outflow was $31.5M for Q1 2026, with $109.6M used in investing activities and $164.4M provided by financing activities.

Outlook and guidance

• Cash position expected to fund planned clinical milestones and operational investments into late 2027.

• Management anticipates significant increases in R&D and manufacturing expenses as clinical and preclinical programs advance.

• Multiple clinical data readouts and regulatory engagements anticipated in 2026 across lead programs.

• Manufacturing expansion, including Chicago and Los Angeles sites, to support future clinical and commercial needs.

• Additional capital may be required for future growth, acquisitions, or commercialization efforts.